Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centers for Disease Control and Prevention | FED |
Not provided
Not provided
Not provided
Not provided
While COVID-19 (coronavirus disease 2019) is an important emergent issue for all in the country, there is a significant number of people in the population who are especially vulnerable to the potential impact that the novel coronavirus epidemic may have on their health. The overall purpose of the study is to investigate: (1) the dynamics of COVID-19 infection among people living with HIV and health care workers providing HIV services; (2) the provision of HIV and HIV/TB care and treatment services at health facilities, within the scope of COVID-19 or in the context of COVID-19 and; (3) the perceptions of COVID-19 and access to care among people living with HIV and health care workers providing HIV services.
The protocol is designed to assess prevalence and incidence of COVID-19 among PLHIV and health care workers. Additionally, we aim to evaluate the effect of the COVID-19 epidemic on clinical and immunological outcomes and health care service delivery among PLHIV and HCWs providing HIV services in Mozambique, as well as monitoring breakthrough infections after vaccination. This will facilitate timely estimates of transmissibility of SARS-CoV-2, and of the severity of COVID-19 infection among PLHIV and HCWs providing HIV services, as well as inform public health responses to these vulnerable populations. In Mozambique, this is particularly important as health systems are operating at capacity, and resources to expand services in the country are limited. It is in this context that a novel respiratory pathogen, SARS-CoV-2, could have a potentially severe impact in Mozambique among its estimated 2.2 million HIV-infected persons and the health care providers caring for them. The study protocol will be implemented at national level in up to 11 provinces of Mozambique. Results will be used primarily for program improvement and strengthening and will support the Ministry of Health in the decision making on strategies for the COVID-19 response.
Goal The overarching goal of this protocol is to determine the incidence, prevalence, and clinical manifestations of SARS-CoV-2 among patients living with HIV and healthcare workers providing HIV services, and to assess the knowledge, attitudes and practices (KAP) and the impact that COVID-19 has on them and on the healthcare system.
Objectives Primary Objectives
Secondary Objectives
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 (SARS-CoV-2 uninfected) | Participants who test negative on the SARS-CoV-2 rapid test and are not considered at risk of COVID-19 or who have a negative RNA-PCR SARS-CoV-2 test result at baseline. | ||
| Cohort 2 (SARS-CoV-2 infected) | Participants who test positive on RNA-PCR SARS-CoV-2. | ||
| Cohort 3 (SARS-CoV-2 exposed) | Participants who have a positive SARS-CoV-2 rapid test result and are not considered to be at risk of active COVID-19 infection or have a negative RNA-PCR SARS-CoV-2 test. | ||
| Cohort 4 ( Vaccinated) | Participants who declare having received at least one dose of COVID-19 vaccine (verbally or by showing vaccination card) at inclusion (for HCW or PLHIV) or at any follow-up visit (PLHIV) will be followed in this cohort. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Disease Severity | Any disease severity considered as any with severe or critical disease, as per WHO definition. | month 6 |
Not provided
Not provided
Inclusion Criteria:
PLHIV enrolled in HIV care
HCWs offering HIV services
Exclusion Criteria:
PLHIV enrolled in HIV care
HCWs offering HIV services
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Edna Viegas, MD, PhD | INS-CISPOC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| INSMozambique | Maputo | Mozambique |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37280029 | Derived | De Schacht C, Nhacule E, Belo C, Young PW, Bhatt N, Junior F, Pimentel De Gusmao E, Muquingue H, Muteerwa A, Bila D, Ouenzar MA, Madede T, Cumbane R, Amorim G, Viegas E; COVIV Study Collaborative Group. Measuring the burden of SARS-CoV-2 infection among persons living with HIV and healthcare workers and its impact on service delivery in Mozambique: protocol of a prospective cohort study. BMJ Open. 2023 Jun 6;13(6):e068988. doi: 10.1136/bmjopen-2022-068988. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
If participants have a positive rapid test or are considered eligible for RNA-PCR SARS-CoV-2 testing, 10mL (mililliters) of venous blood (6mL EDTA and 4mL serum tubes) will be collected as stored samples for future research related to COVID-19.
All participants will have DBS sample collected.
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |